MedWatch

Coloplast expects organic growth of 7 percent next year

For the financial year 2021/2022, Coloplast is anticipating an organic growth of 7 percent in current exchange rates and an EBIT margin of 32 percent, it reports in connection with the release of its year-end results from the skewed 2020/21 financial year.

Photo: Coloplast / PR

Medtech company Coloplast is expecting to reach the same organic growth it landed on in the financial year that just ended for the next financial year of 2021/2022, it states in its year-end report from 2020/2021, which was released on Monday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs